Nalbuphine for Cough Caused by Idiopathic Pulmonary Fibrosis

In a recent study, researchers found that nalbuphine ER effectively reduced cough frequency in patients with idiopathic pulmonary fibrosis (IPF), a condition with limited treatment options. The trial showed that higher doses of the drug led to even greater improvements over six weeks compared to a placebo. While this is promising news for those suffering from IPF-related chronic cough, more research is needed to fully understand the drug's long-term effects and optimal dosing for real-world use. This development is significant as it may offer a new therapeutic avenue for managing a debilitating symptom in a patient group with few effective treatments.